Most Shorted Stocks
TRVI is part of our most shorted stocks screen list, indicating it has a high short interest.
TREVI THERAPEUTICS INC (TRVI) Stock Price & Overview
NASDAQ:TRVI • US89532M1018
Current stock price
14.635 USD
+0.02 (+0.1%)
Last:
The current stock price of TRVI is 14.635 USD. Today TRVI is up by 0.1%. In the past month the price increased by 35.87%. In the past year, price increased by 125.97%.
TRVI Key Statistics
52-Week Range5.3801 - 16.12
Current TRVI stock price positioned within its 52-week range.
1-Month Range10.25 - 16.12
Current TRVI stock price positioned within its 1-month range.
- Market Cap
- 1.879B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.32
- Dividend Yield
- N/A
TRVI Stock Performance
Today
+0.1%
1 Week
+4.13%
1 Month
+35.87%
3 Months
+46.35%
Longer-term
6 Months +39.11%
1 Year +125.97%
2 Years +398.98%
3 Years +325.00%
5 Years +538.43%
10 Years N/A
TRVI Stock Chart
TRVI Stock Screens
TRVI currently appears in the following ChartMill screener lists.
TRVI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TRVI. When comparing the yearly performance of all stocks, TRVI is one of the better performing stocks in the market, outperforming 95.1% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRVI. TRVI has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TRVI Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.06
Revenue Reported
EPS Surprise 40.09%
Revenue Surprise %
TRVI Forecast & Estimates
18 analysts have analysed TRVI and the average price target is 21.93 USD. This implies a price increase of 49.85% is expected in the next year compared to the current price of 14.635.
Analysts
Analysts85.56
Price Target21.93 (49.85%)
EPS Next Y-43.49%
Revenue Next YearN/A
TRVI Groups
Sector & Classification
TRVI Financial Highlights
Over the last trailing twelve months TRVI reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 31.91% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-42.76M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.1% | ||
| ROE | -23.33% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%45.45%
Sales Q2Q%N/A
EPS 1Y (TTM)31.91%
Revenue 1Y (TTM)N/A
TRVI Ownership
Ownership
Inst Owners93.45%
Shares128.40M
Float113.97M
Ins Owners0.76%
Short Float %13.42%
Short Ratio11.6
TRVI Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.3 | 853.191B | ||
| JNJ | JOHNSON & JOHNSON | 17.67 | 544.731B | ||
| MRK | MERCK & CO. INC. | 22.13 | 278.01B | ||
| PFE | PFIZER INC | 8.97 | 155.349B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.28 | 121.259B | ||
| ZTS | ZOETIS INC | 16.54 | 49.697B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.59 | 28.547B | ||
| VTRS | VIATRIS INC | 5.8 | 17.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.37 | 11.291B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.359B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.199B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.101B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.4 | 4.797B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TRVI
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
IPO: 2019-05-07
TREVI THERAPEUTICS INC
195 Church Street, 16Th Floor
New Haven CONNECTICUT 06510 US
CEO: Jennifer Good
Employees: 26
Phone: 18004831140
TREVI THERAPEUTICS INC / TRVI FAQ
Can you describe the business of TREVI THERAPEUTICS INC?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Can you provide the latest stock price for TREVI THERAPEUTICS INC?
The current stock price of TRVI is 14.635 USD. The price increased by 0.1% in the last trading session.
Does TRVI stock pay dividends?
TRVI does not pay a dividend.
How is the ChartMill rating for TREVI THERAPEUTICS INC?
TRVI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in TREVI THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRVI.
Who owns TREVI THERAPEUTICS INC?
You can find the ownership structure of TREVI THERAPEUTICS INC (TRVI) on the Ownership tab.